Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
Abstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis iden...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-11-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202002015 |
id |
doaj-40ec1918116a4fb3896d28a1646b5c7f |
---|---|
record_format |
Article |
spelling |
doaj-40ec1918116a4fb3896d28a1646b5c7f2020-11-25T04:10:44ZengWileyAdvanced Science2198-38442020-11-01722n/an/a10.1002/advs.202002015Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy ResistanceZulfikar Azam0Shing‐Shun Tony TO1Bakhos A. Tannous2Experimental Therapeutics and Molecular Imaging Unit Department of Neurology Neuro‐Oncology Division Massachusetts General Hospital and Harvard Medical School Boston MA 02129 USADepartment of Health Technology and Informatics The Hong Kong Polytechnic University Hong Kong 999077 ChinaExperimental Therapeutics and Molecular Imaging Unit Department of Neurology Neuro‐Oncology Division Massachusetts General Hospital and Harvard Medical School Boston MA 02129 USAAbstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis identifies different molecular subtypes with varying prognosis, while multiple subtypes can reside in the same tumor. Cellular plasticity among different subtypes in response to therapies or during recurrence adds another hurdle in the treatment of GBM. This phenotypic shift is induced and sustained by activation of several pathways within the tumor itself, or microenvironmental factors. In this review, the dynamic nature of cellular shifts in GBM and how the tumor (immune) microenvironment shapes this process leading to therapeutic resistance, while highlighting emerging tools and approaches to study this dynamic double‐edged sword are discussed.https://doi.org/10.1002/advs.202002015clinical outcomeglioblastoma (GBM)mesenchymal transitionmolecular subtypestherapy responsestumor microenvironment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zulfikar Azam Shing‐Shun Tony TO Bakhos A. Tannous |
spellingShingle |
Zulfikar Azam Shing‐Shun Tony TO Bakhos A. Tannous Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance Advanced Science clinical outcome glioblastoma (GBM) mesenchymal transition molecular subtypes therapy responses tumor microenvironment |
author_facet |
Zulfikar Azam Shing‐Shun Tony TO Bakhos A. Tannous |
author_sort |
Zulfikar Azam |
title |
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance |
title_short |
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance |
title_full |
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance |
title_fullStr |
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance |
title_full_unstemmed |
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance |
title_sort |
mesenchymal transformation: the rosetta stone of glioblastoma pathogenesis and therapy resistance |
publisher |
Wiley |
series |
Advanced Science |
issn |
2198-3844 |
publishDate |
2020-11-01 |
description |
Abstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis identifies different molecular subtypes with varying prognosis, while multiple subtypes can reside in the same tumor. Cellular plasticity among different subtypes in response to therapies or during recurrence adds another hurdle in the treatment of GBM. This phenotypic shift is induced and sustained by activation of several pathways within the tumor itself, or microenvironmental factors. In this review, the dynamic nature of cellular shifts in GBM and how the tumor (immune) microenvironment shapes this process leading to therapeutic resistance, while highlighting emerging tools and approaches to study this dynamic double‐edged sword are discussed. |
topic |
clinical outcome glioblastoma (GBM) mesenchymal transition molecular subtypes therapy responses tumor microenvironment |
url |
https://doi.org/10.1002/advs.202002015 |
work_keys_str_mv |
AT zulfikarazam mesenchymaltransformationtherosettastoneofglioblastomapathogenesisandtherapyresistance AT shingshuntonyto mesenchymaltransformationtherosettastoneofglioblastomapathogenesisandtherapyresistance AT bakhosatannous mesenchymaltransformationtherosettastoneofglioblastomapathogenesisandtherapyresistance |
_version_ |
1724419358297423872 |